PHB is a reported oncogene and tumor suppressor in gastric cancer. Here, we evaluated whether the PHB copy number and the rs6917 polymorphism affect its expression in gastric cancer. Down-regulation and up-regulation of PHB were observed in the evaluated tumors. Reduced expression was associated with tumor dedifferentiation and cancer initiation. The T allele of the rs6917 polymorphism was associated with reduced PHB mRNA levels. Moreover, the up-regulation of PHB appeared to be regulated by the gain of additional gene copies. Thus, PHB copy number variation and differential expression of the rs6917 polymorphism may play a role in PHB transcriptional regulation.
References
[1]
Jemal A, Bray F (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90. doi: 10.3322/caac.20107
[2]
Panani AD (2008) Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett 266: 99–115. doi: 10.1016/j.canlet.2008.02.053
[3]
Takeno SS, Leal MF, Lisboa LC, Lipay MV, Khayat AS, et al. (2009) Genomic alterations in diffuse-type gastric cancer as shown by high-resolution comparative genomic hybridization. Cancer Genet Cytogenet 190: 1–7. doi: 10.1016/j.cancergencyto.2008.09.007
[4]
Khayat AS, Guimaraes AC, Calcagno DQ, Seabra AD, Lima EM, et al. (2009) Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol 9: 55. doi: 10.1186/1471-230x-9-55
[5]
Burbano RR, Assumpcao PP, Leal MF, Calcagno DQ, Guimaraes AC, et al. (2006) C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res 26: 2909–2914.
[6]
Assumpcao PP, Ishak G, Chen ES, Takeno SS, Leal MF, et al. (2006) Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence in situ hybridization in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet Cytogenet 169: 45–49. doi: 10.1016/j.cancergencyto.2006.03.019
[7]
Leal MF, Calcagno DQ, Borges da Costa Jde F, Silva TC, Khayat AS, et al. (2010) MYC, TP53, and chromosome 17 copy-number alterations in multiple gastric cancer cell lines and in their parental primary tumors. J Biomed Biotechnol 2011: 631268. doi: 10.1155/2011/631268
[8]
Leal MF, Martins do Nascimento JL, da Silva CE, Vita Lamarao MF, Calcagno DQ, et al. (2009) Establishment and conventional cytogenetic characterization of three gastric cancer cell lines. Cancer Genet Cytogenet 195: 85–91. doi: 10.1016/j.cancergencyto.2009.04.020
[9]
Nijtmans LG, de Jong L, Artal Sanz M, Coates PJ, Berden JA, et al. (2000) Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. Embo J 19: 2444–2451. doi: 10.1093/emboj/19.11.2444
[10]
Theiss AL, Sitaraman SV (2011) The role and therapeutic potential of prohibitin in disease. Biochim Biophys Acta 1813: 1137–1143. doi: 10.1016/j.bbamcr.2011.01.033
[11]
Jupe ER, Liu XT, Kiehlbauch JL, McClung JK, Dell’Orco RT (1996) Prohibitin in breast cancer cell lines: loss of antiproliferative activity is linked to 3′ untranslated region mutations. Cell Growth Differ 7: 871–878.
[12]
Manjeshwar S, Branam DE, Lerner MR, Brackett DJ, Jupe ER (2003) Tumor suppression by the prohibitin gene 3′untranslated region RNA in human breast cancer. Cancer Res 63: 5251–5256.
[13]
Zhou TB, Yin SS, Huang JJ, Ou C (2012) Relationship between the prohibitin 3′ untranslated region C>T gene polymorphism and cancer susceptibility–results of a meta-analysis. Asian Pac J Cancer Prev 13: 3319–3323. doi: 10.7314/apjcp.2012.13.7.3319
[14]
Francisco G, Goncalves FT, Luiz OC, Saito RF, Toledo RA, et al. (2013) Polymorphisms in the p27kip-1 and prohibitin genes denote novel genes associated with melanoma risk in Brazil, a high ultraviolet index region. Melanoma Res 23: 231–236. doi: 10.1097/cmr.0b013e3283612483
[15]
Ryu JW, Kim HJ, Lee YS, Myong NH, Hwang CH, et al. (2003) The proteomics approach to find biomarkers in gastric cancer. J Korean Med Sci 18: 505–509.
[16]
Wang KJ, Wang RT, Zhang JZ (2004) Identification of tumor markers using two-dimensional electrophoresis in gastric carcinoma. World J Gastroenterol 10: 2179–2183.
[17]
He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, et al. (2004) Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 4: 3276–3287. doi: 10.1002/pmic.200300916
[18]
Kang X, Zhang L, Sun J, Ni Z, Ma Y, et al. (2008) Prohibitin: a potential biomarker for tissue-based detection of gastric cancer. J Gastroenterol 43: 618–625. doi: 10.1007/s00535-008-2208-3
[19]
Ren H, Du N, Liu G, Hu HT, Tian W, et al. (2006) Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. World J Gastroenterol 12: 2789–2792.
[20]
Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW (2004) The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res 14: 491–499.
[21]
Liu T, Tang H, Lang Y, Liu M, Li X (2009) MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 273: 233–242. doi: 10.1016/j.canlet.2008.08.003
[22]
Lauren P (1965) The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. an Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand 64: 31–49.
[23]
Washington K (2010) 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 17: 3077–3079. doi: 10.1245/s10434-010-1362-z
[24]
Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45. doi: 10.1093/nar/29.9.e45
[25]
Ge B, Gurd S, Gaudin T, Dore C, Lepage P, et al. (2005) Survey of allelic expression using EST mining. Genome Res 15: 1584–1591. doi: 10.1101/gr.4023805
[26]
Lo HS, Wang Z, Hu Y, Yang HH, Gere S, et al. (2003) Allelic variation in gene expression is common in the human genome. Genome Res 13: 1855–1862.
[27]
Nuell MJ, Stewart DA, Walker L, Friedman V, Wood CM, et al. (1991) Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells. Mol Cell Biol 11: 1372–1381.
[28]
Jupe ER, Liu XT, Kiehlbauch JL, McClung JK, Dell’Orco RT (1996) The 3′ untranslated region of prohibitin and cellular immortalization. Exp Cell Res 224: 128–135. doi: 10.1006/excr.1996.0120
[29]
Manjeshwar S, Lerner MR, Zang XP, Branam DE, Pento JT, et al. (2004) Expression of prohibitin 3′ untranslated region suppressor RNA alters morphology and inhibits motility of breast cancer cells. J Mol Histol 35: 639–646. doi: 10.1007/s10735-004-2185-7
[30]
Artal-Sanz M, Tavernarakis N (2009) Prohibitin and mitochondrial biology. Trends Endocrinol Metab 20: 394–401. doi: 10.1016/j.tem.2009.04.004
[31]
Leal MF, Chung J, Calcagno DQ, Assumpcao PP, Demachki S, et al. (2012) Differential proteomic analysis of noncardia gastric cancer from individuals of northern Brazil. PLoS One 7: e42255. doi: 10.1371/journal.pone.0042255
[32]
Warburg O (1956) On respiratory impairment in cancer cells. Science 124: 269–270. doi: 10.1126/science.124.3215.267
[33]
Tang L, Zhao Y, Nie W, Wang Z, Guan X (2013) 3′ untranslated region 1630 C>T polymorphism of prohibitin increases risk of breast cancer. Onco Targets Ther 6: 177–182. doi: 10.2147/ott.s40997
[34]
Kuersten S, Goodwin EB (2003) The power of the 3′ UTR: translational control and development. Nat Rev Genet 4: 626–637. doi: 10.1038/nrg1125
[35]
Jia J, Yao P, Arif A, Fox PL (2013) Regulation and dysregulation of 3′UTR-mediated translational control. Curr Opin Genet Dev 23: 29–34. doi: 10.1016/j.gde.2012.12.004
[36]
Li J, Lu X (2013) The emerging roles of 3′ untranslated regions in cancer. Cancer Lett 337: 22–25. doi: 10.1016/j.canlet.2013.05.034
Terada R, Yasutake T, Yamaguchi E, Hisamatsu T, Nakamura S, et al. (1999) Higher frequencies of numerical aberrations of chromosome 17 in primary gastric cancers are associated with lymph node metastasis. J Gastroenterol 34: 11–17. doi: 10.1007/s005350050210
[39]
Kitayama Y, Igarashi H, Watanabe F, Maruyama Y, Kanamori M, et al. (2003) Nonrandom chromosomal numerical abnormality predicting prognosis of gastric cancer: a retrospective study of 51 cases using pathology archives. Lab Invest 83: 1311–1320. doi: 10.1097/01.lab.0000087622.80751.c5
[40]
Tavares A, Gandra A, Viveiros F, Cidade C, Maciel J (2013) Analysis of clinicopathologic characteristics and prognosis of gastric cancer in young and older patients. Pathol Oncol Res 19: 111–117. doi: 10.1007/s12253-012-9530-z
[41]
Kitamura K, Yamaguchi T, Taniguchi H, Hagiwara A, Yamane T, et al. (1996) Clinicopathological characteristics of gastric cancer in the elderly. Br J Cancer 73: 798–802.
[42]
Maehara Y, Emi Y, Tomisaki S, Oshiro T, Kakeji Y, et al. (1996) Age-related characteristics of gastric carcinoma in young and elderly patients. Cancer 77: 1774–1780. doi: 10.1002/(sici)1097-0142(19960501)77:9<1774::aid-cncr3>3.0.co;2-c
[43]
Buffart TE, Carvalho B, Hopmans E, Brehm V, Kranenbarg EK, et al. (2007) Gastric cancers in young and elderly patients show different genomic profiles. J Pathol 211: 45–51. doi: 10.1002/path.2085
